IntroductionChinese hamster ovary (CHO) cell lines are the most commonly used mammalian cells both for research and for industrial recombinant protein therapeutics production. In the last decades, CHO cell productivity has reached gram‐per liter mark, which is a 100‐fold increase since the first product approval of tissue plasminogen activator (tPA), in 1986.Due to their metabolic plasticity, immense adaptability, and ease of maintenance CHO cells remain widely exploited for various purposes. Discovery of auxotrophic mutants deficient in the dihydrofolate reductase (DHFR) enzyme aided establishment of the expression system, allowing easy clonal selection and gene amplification. The resulting double deletion cell line CHO‐DG44 became a workhorse for many recombinant products. CHO cells are capable of correct protein folding and post‐translational modifications, compatible with the human immune system, increasing their value for therapeutic recombinant product production.Despite recent advances, the generation of high‐producing cell lines is still a very demanding, arduous, and multi‐step process which involves vector design, transformation, and an elaborate selection for high producing clones. It is estimated that the complete process required for the establishment of designated stable producing cell line can require 4 to 12 months.Many technologies for optimization of heterologous protein production have been generated over the last
Biotechnology Journal – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud